ReviewMedicina (Kaunas, Lithuania)2022
Up-to-Date Procedures in Female Stress Urinary Incontinence Surgery: A Concise Review on Bulking Agents Procedures.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- How Long Does Urinary Continence Last After Treatment with Intravaginal COInternational urogynecology journal · 2025Trial
- Regenerative Medicine Approaches to Stress Urinary Incontinence.Biomimetics (Basel, Switzerland) · 2026Review
- Electrotherapy Plus Photobiostimulation for the Treatment of Mild Pelvic Organ Prolapse and Stress Urinary Incontinence.Journal of clinical medicine · 2026Article
- Guarding Reflex Inhibition Training Reduces Postoperative Urinary Retention After Urethral Bulking for Stress Urinary Incontinence: A Retrospective Single-Center Study.Journal of clinical medicine · 2025Article
- Assessment of Migration of the Urethral Bulking Agent Zhoabex GInternational journal of molecular sciences · 2025Article
- Article
- Urethral Bulking Agents for the Treatment of Urinary Incontinence: Efficacy, Safety, and Impact on the Overactive Bladder Symptoms with an Underlying Detrusor Overactivity.Journal of clinical medicine · 2024Article
- Long-Term Outcomes of Tension-Free Vaginal Tape Obturator: Efficacy and Safety at Long-Term Follow-Up.Journal of clinical medicine · 2024Article
- Italian validation of the Pelvic Floor Distress Inventory (PFDI-20) questionnaire.International urogynecology journal · 2023Article
- Flat Magnetic Stimulation for Stress Urinary Incontinence: A 3-Month Follow-Up Study.Healthcare (Basel, Switzerland) · 2023Article
- Does the Polydimethylsiloxane Urethral Injection (MacroplastiqueMedicina (Kaunas, Lithuania) · 2023Article
- Flat Magnetic Stimulation for Stress Urinary Incontinence: A Prospective Comparison Study.Bioengineering (Basel, Switzerland) · 2023Article
- Efficacy and Adverse Effects After Single-Incision Slings for Women with Stress Urinary Incontinence: A 12-Year Follow-Up.International journal of women's health · 2023Article
- Urethral Injury After Vaginal Birth and Stress Urinary Incontinence: Bulking Agents are Feasible Options.International journal of women's health · 2023Article
- Effectiveness and safety of polyacrylamide hydrogel injection for female stress urinary incontinence: A systematic review and single-arm meta-analysis.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To avoid complications related to mid-urethral slings (MUS), alternative procedures to treat stress urinary incontinence (SUI), such as urethral bulking agents (UBAs) have been adopted. The aim of this review is to narratively report the efficacy and safety of UBAs for SUI treatment. For this review, research from PubMed and EMBASE was performed to evaluate relevant studies that were undertaken from January 2012 to January 2022. Nineteen prospective studies were included. Several definitions of subjective and objective success were adopted. At a follow-up of <24 months, significant improvement was widely observed, even if with a heterogeneous rate of success between 32.7−90%, and a reinjection rate of 8.3−77.3%. Compared with other procedures, MUS resulted as significantly superior to UBAs but was balanced by a higher complication rate. Acute urinary retention, urinary tract infection and de novo urgency, and other complications, such as injection site rupture, urethral erosion and particle migration have been described after UBAs. SUI after UBAs treatment resulted in improvements in all studies and can be considered a safe and effective option to treat SUI. However, homogenous and longer-term data lack, limiting general recommendations. Thus, larger RCTs evaluating long-term effects are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.